Novo Nordisk Shares Plunge 10% Following Failed Heart Disease Trial

Copenhagen, Friday, 31 July 2026.
Novo Nordisk stock tumbled 10% on July 31, 2026, after its experimental drug ziltivekimab failed to reduce major cardiovascular risks, raising pipeline concerns beyond its flagship GLP-1 treatments.